Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074105 | 0.84 | AKR1C3 (0.40) | PTGDR2AKR1C3AKR1C2CNR2PTGS2 | |
| SCHEMBL397819 | 0.73 | PTGDR2 (0.78) | PTGDR2 | |
| SCHEMBL2074087 | 0.71 | AKR1C3 (0.76) | PTGDR2AKR1C3AKR1C2CNR2PTGS2 | |
| SCHEMBL399816 | 0.69 | EGFR (0.43) | AKR1C2MEN1CYP1A2KMT2AEGFR | |
| SCHEMBL17102822 | 0.67 | EGFR (0.56) | AKR1C3AKR1C2CNR2PTGS2CNR1 | |
| SCHEMBL1295475 | 0.66 | ALOX5 (0.47) | MEN1CYP1A2KMT2A | |
| SCHEMBL10732151 | 0.66 | EGFR (0.46) | MEN1CYP1A2KMT2AEGFR | |
| Hydrochloric Acid SCHEMBL27680687 | 0.65 | ALOX5 (0.46) | MEN1CYP1A2KMT2A | |
| SCHEMBL463206 | 0.64 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL9430379 | 0.63 | KMT2A (0.41) | MEN1CYP1A2KMT2AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | HRH2, HRH1, TSLP | PTGDR2 13/4885AKR1C3 1424/4885AKR1C2 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.